Advertisement

Related Videos

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Focus on Optimized Dosing of Ibrutinib Panel Discussion

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Advertisement

Advertisement




Dec
18
Today In Oncology
Intravesical Oncolytic Adenovirus Delivers High Complete Response Rates in BCG-Naive, High-Risk, NMIBC With Carcinoma in Situ
Distant Disease-Free Survival as a Surrogate for Overall Survival in Trials of Neoadjuvant Therapy in Early Breast Cancer
FDA Approves Durvalumab With FLOT for Resectable Gastric-GEJ Adenocarcinoma
10-Year Outcomes With Adjuvant Metronomic Capecitabine in Early Triple-Negative Breast Cancer
FDA Approves Amivantamab and Hyaluronidase-lpuj for Subcutaneous Injection
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo